Valneva deal with Emergent BioSolutions for development of vaccines in the EB66 cell line

11 March 2014

European biotechnology company Valneva (Euronext: VLA) has signed a new research license agreement and transferred an existing commercial agreement to Emergent BioSolutions (NYSE:EBS), to develop new vaccines using Valneva’s EB66 cell line.

The agreements will grant Emergent and its affiliates the rights to research and commercialize new and existing vaccine candidates using Valneva’s EB66 technology. The commercial license, which was initially granted to the Oxford-Emergent Tuberculosis Consortium (OETC) for the development of tuberculosis vaccines, will be transferred to Emergent.

Undisclosed upfront and other payments to be made

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK